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ABSTRACT
Objectives The Educational Needs Assessment Tool
(ENAT) is a self-completed questionnaire, which allows
patients with arthritis to prioritise their educational
needs. The aim of this study was to evaluate the effects
of needs-based patient education on self-efﬁcacy, health
outcomes and patient knowledge in people with
rheumatoid arthritis (RA).
Methods Patients with RA were enrolled into this
multicentre, single-blind, parallel-group, pragmatic
randomised controlled trial. Patients were randomised to
either the intervention group (IG) where patients
completed ENAT, responses of which were used by the
clinical nurse specialist to guide patient education; or
control group (CG) in which they received patient
education without the use of ENAT. Patients were seen
at weeks 0, 16 and 32. The primary outcome was self-
efﬁcacy (Arthritis Self Efﬁcacy Scale (ASES)-Pain and
ASES-Other symptoms). Secondary outcomes were health
status (short form of Arthritis Impact Measurement Scale
2, AIMS2-SF) and patient knowledge questionnaire-RA.
We investigated between-group differences using
analysis of covariance, adjusting for baseline variables.
Results A total of 132 patients were recruited (IG=70
and CG=62). Their mean (SD) age was 54 (12.3) years,
56 (13.3) years and disease duration 5.2 (4.9) years,
6.7 (8.9) years for IG and CG, respectively. There were
signiﬁcant between-group differences, in favour of IG at
week 32 in the primary outcomes, ASES-Pain, mean
difference (95% CI) −4.36 (1.17 to 7.55), t=−2.72,
p=0.008 and ASES-Other symptoms, mean difference
(95% CI) −5.84 (2.07 to 9.62), t=−3.07, p=0.003. In
secondary outcomes, the between-group differences
favoured IG in AIMS2-SF Symptoms and AIMS2-SF
Affect. There were no between-group differences in other
secondary outcomes.
Conclusions The results suggest that needs-based
education helps improve patients’ self-efﬁcacy and some
aspects of health status.
Trial registration number ISRCTN51523281.
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic chronic
inﬂammatory disease characterised by joint swel-
ling, joint tenderness and destruction of synovial
joints, potentially leading to severe disability and
premature mortality.1 2 RA has a negative impact
on individuals’ physical and psychological
functioning, which contributes signiﬁcantly to the
burden of disease.2–4 The primary goal of treat-
ment is to suppress disease activity, thus preventing
structural damage and optimising function and
social participation.5
Patient education can be deﬁned as planned orga-
nised learning experiences designed to support
and enable people to manage life with their condi-
tion and optimise their health and well-being.6
Patient education has been recommended as an
integral part of management in RA as this prepares
the patient to undertake self-management activities
and adhere to all their treatments.6–8 Patient educa-
tion needs to aim at improving patients’ self-
efﬁcacy as this is a predictor of self-management
and other health outcomes.9–12 Furthermore, there
is now an understanding that effective management
of chronic conditions must be based on shared
decision-making between the patient and healthcare
providers,10 13 the principle which underlies the
current RA treatment recommendations.5 14 15
In rheumatology services, provision of patient
education is considered to be an important role of
the rheumatology nurses8 16 17 and patients value
the education received from them.18–22 This has
been supported by nurse-led care effectiveness
randomised controlled trials (RCTs)21–27 and
European League against Rheumatism (EULAR)
recommendations for the role of the nurse in
inﬂammatory arthritis.28 Although people with RA
value patient education, there may be a discrepancy
between their perception of their educational needs
and the perception of their providers.29 If the pro-
vided education does not match patients’ perceived
educational needs, it may not be acted upon, which
would be a waste of health service resource. The
Educational Needs Assessment Tool (ENAT) is a
self-completed questionnaire, which allows patients
with arthritis to prioritise their educational
needs.30 The tool was developed with patients and
it has 39 items which are grouped into seven
domains: managing pain, movement, feelings, arth-
ritis process, treatments, self-help measures and
support. ENAT has been validated as a generic
instrument for rheumatic diseases across nine
European countries.31–33 It can be used as a clinical
tool to guide patient education or as an outcome
measure in research. Completion of ENAT just
before the clinical consultation enables the health
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professional to provide education based on the patient’s imme-
diate priorities.
Recently, EULAR evidence-based recommendations for
patient education in inﬂammatory arthritis have been published6
and they have recommended that content and delivery of
patient education should be individually tailored and needs-
based. Recent systematic reviews6 11 34 and RCTs12 21 22 have
shown that tailored patient education is likely to improve health
outcomes including self-efﬁcacy. Two of the RCTs21 22 used
ENAT as an outcome measure but not as a clinical tool to guide
individual patient education. The present study is the ﬁrst RCT
to use ENAT as part of the intervention. The aim of this study
was to evaluate the effects of needs-based patient education on
self-efﬁcacy, patient knowledge and health status (physical func-
tion, symptoms, role/work, social interaction and psychological
status/affect).
METHODS
Study design
This was a multicentre, single-blind, parallel-group, pragmatic
RCT conducted between April 2010 and August 2013. The trial
comprised two groups: (1) The need-based patient education
(the intervention group, IG) and (2) patient education given in
the usual way, without the use of ENAT (the control group,
CG). The study was conducted in accordance with Good
Clinical Practice in research and the Research Governance
Framework for Health and Social Care.35 All patients gave their
written consent after having received full information about the
study objectives and content. This trial was registered
(ISRCTN51523281) and the protocol has been published
elsewhere.36
Participants and randomisation
Patients were identiﬁed from the lists of new clinic referrals at
six rheumatology centres in Yorkshire, Shropshire, Coventry,
Devon and London, UK. The inclusion criteria were: a positive
diagnosis of RA done by a rheumatologist, using the 1987
American College of Rheumatology (ACR) criteria37 or the
2010 ACR/EULAR criteria38 and age 18 years or older. The
exclusion criteria were: suffering from a severe mental health
problem and inability to complete questionnaire unaided.
Patients who fulﬁlled the inclusion criteria were sent a study
invitation letter with patient information sheet by post. At each
centre, patients were approached by a recruiter (a research nurse
or a research associate) who was not involved in giving study
interventions. Those who agreed to participate were asked to
attend their usual clinic appointment and their written consent
was sought at this visit. Following informed consent, patients
were randomised on a 1:1 basis to either the needs-based educa-
tion group or the usual care group. The randomisation was by
block randomisation done by computer generated random
numbers. The results of the randomisation were held at each
centre in sealed in brown envelopes.
Blinding
The patients (in CG and IG) were blinded to the nature of the
intervention. In the patient information leaﬂet, all patients were
informed about the purpose of the study and about completing
‘some’ questionnaires prior to their clinic consultation. During
the clinic visit, patients were seen at separate appointment times
and they were not told which group they were in. Although
both groups completed a set of questionnaires and were given
patient education, they did not know that IG additionally com-
pleted ENAT as part of their questionnaire set and that their
responses were used to guide patient education. The clinical
nurse specialists (CNS) who provided the patient education
were not blinded.
Interventions
Rheumatology CNS saw all patients (CG and IG) in the clinic
on three occasions, at weeks 0, 16 and 32. These time points
relate to the normal follow-up practice. As a part of the usual
care, the CNS monitored disease activity, other symptoms and
patient coping, adherence to treatments and side effects. Other
activities included making referrals to other health professionals,
providing psychosocial support and giving patient education
without the use of ENAT. Consultations in IG were similar to
CG except that patients completed ENAT at each clinic visit,
prior to their consultation with the CNS and their responses
were used to direct patient education at that time. After each
consultation in both groups, the CNS completed a form to
record the patient education which has been provided.
Outcome measures
The primary outcome was perceived self-efﬁcacy, measured by
the short form of the Arthritis Self Efﬁcacy Scale (ASES)39 at
week 32. The questionnaire has been validated in the UK and it
has two subscales ASES-Pain and ASES-Other symptoms with
score ranges 5–50 and 6–60, respectively, higher scores reﬂect-
ing higher self-efﬁcacy. Secondary outcomes were: (1) disease-
speciﬁc health status assessed by the short form of Arthritis
Impact Measurement Scale 2 (AIMS2-SF),40 which measures
physical function, symptoms (pain, stiffness and sleep), role,
social interaction and psychological status. AIMS2-SF is a valid
and reliable measure in RA and each subscale score ranges from
0 to 10, 0 being good health status,40 and (2) patient knowledge
of their disease, measured by Patient Knowledge Questionnaire
(PKQ-RA).41 PKQ-RA has been shown to be a valid, reliable
and sensitive tool for measuring the acquisition of RA knowl-
edge following educational intervention.41 The score ranges
from 0 to 12, higher scores indicating higher level of knowl-
edge. All outcomes were measured at weeks 0, 16 and 32.
Attempts were made to follow-up all randomised participants
with incomplete data, by telephone and letters with follow-up
questionnaires. Additionally, although in this study, ENAT was
used as a clinical tool and not as an outcome measure, we ana-
lysed ENAT scores of IG aiming to assess possible trends in
patients’ educational needs over time.
Sample size calculation
The sample size calculation was based on the clinically meaning-
ful change in the ASES (ASES-Pain and ASES-Other symptoms)
scores.39 Assuming a mean difference of 5.5 (SD=10.0) as
being clinically meaningful for the ASES-Pain and ASES-Other
symptoms scales with a 5% signiﬁcance level and 80% power,
52 patients were needed per arm of the trial (total=104). To
allow for a 25% dropout rate, 130 patients were recruited.
Data analysis
With the exception of AIMS2-SF work data, which was only
available for participants who were working, all missing data
were imputed via multiple imputation using chained equa-
tions.42 Data was deﬁned as missing if patients failed to com-
plete either the 16-week or the 32-week follow-up. Nine per
cent of responders dropped out of the study at week 16 and
20% dropped out at week 32, therefore 20 imputed data sets
were computed on guidance that at a minimum, the number
needed should approximate the percentage of incomplete
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cases.42 Age, gender, treatment group and baseline PKQ,
ASES-Pain and ASES-Other symptoms scores and AIMS2-SF
symptoms, affect, physical and social scores were included in
the imputation model. All analyses were then undertaken on an
intention-to-treat basis except for the AIMS2-SF work data,
which followed a complete case analysis approach. A conserva-
tive complete case analysis of all data was also undertaken to
assess the effect of the missing data. Summary statistics are pre-
sented as means and 95% CIs for continuous variables and
numbers and percentages for categories. Differences between
treatment groups were investigated using χ2 test (Fisher’s exact
test if the expected cell counts were less than ﬁve) or t test for
categorical and continuous variables, respectively. Repeated
measures analysis of variance was used to look for trends over
time. All analyses were adjusted for baseline values using ana-
lysis of covariance. Bonferroni correction was applied to the
p values for the primary outcomes ASES-Pain and ASES-Other
symptoms in order to avoid type I errors due to multiple
testing.43 Thus for the primary outcome measures p<0.025 was
regarded as statistically signiﬁcant and p<0.05 was regarded as
statistically signiﬁcant for all other tests. STATAV.1244 was used
for all analyses.
RESULTS
Participant characteristics and baseline scores by treatment
group
A total of 132 patients were entered into the study (CG, 62 and
IG, 70). Of the 132 patients who entered the study; 128 (97%)
completed the questionnaires at baseline (60 (97%) CG, 68
(97%) IG), 116 (88%) at week 16 (53 (85%) CG, 63 (90%) IG)
and 102 (77%) at week 32 (47 (76%) CG, 55 (79%) IG).
Figure 1 presents the patient ﬂow chart and table 1 presents the
patient characteristics (and baseline values of outcome measures)
by treatment group.
Group differences in the interventions
The interventions undertaken by both groups are summarised in
the online supplementary table S1. At week 16, there were no
signiﬁcant differences between the two groups in the number of
interventions. At week 32, patients under CG were more likely
to have medication or dosage changes than IG. Predictably,
more patients under CG received patient education on drug
therapy than those in the ENAT group. There were no signiﬁ-
cant differences between the two groups in the mean consult-
ation times and number of referrals to other healthcare workers.
Patient outcomes in the follow-up period
Table 2 presents the between-group differences after adjusting
for baseline values using analysis of covariance in self-efﬁcacy
(ASES) and health status (AIMS2-SF) outcomes at week 16 and
week 32. Table 3 presents the mean score changes over time for
self-efﬁcacy, health status and patients’ knowledge of their RA
over the whole follow-up period (results of repeated measure
analysis of variance).
Self-efﬁcacy
At week 16 there were no signiﬁcant between-group differences
in the ASES scores. At week 32 however, mean scores for
ASES-Pain and ASES-Other symptoms were higher for IG than
CG; ASES-Pain mean difference=4.36, 95% CI 1.17 to 7.55;
t=2.72, p=0.008; ASES-Other symptoms mean differ-
ence=5.84, 95% CI 2.07 to 9.62; t=3.07, p=0.003
Figure 1 Study ﬂow chart/*shared care, Clinical Nurse Specialist care was transferred to the primary care by the hospital.
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(Bonferroni-adjusted p value=0.025 for signiﬁcance at the α
level). Over the whole follow-up period, there were no signiﬁ-
cant changes in ASES scores in CG but IG saw signiﬁcant
improvements in ASES-Pain and ASES-Other symptoms scores
(table 3).
Health status
While there were no signiﬁcant between-group differences at
week 16, there were signiﬁcant between-group differences in
favour of IG at week 32 in AIMS2-SF Symptoms and AIMS2-SF
Affect. There were no signiﬁcant differences in other AIMS2-SF
scores. See table 2. Over the whole follow-up period, IG saw
signiﬁcant decrease in AIMS2-SF scores for symptoms and
affect domains, CG had improvements in the work domain
only. See table 3.
Patients’ knowledge
Online supplementary table S2 presents the number of patients
providing correct answers to each PKQ item and the mean PKQ
score (95% CI) at each time point. There were no signiﬁcant
between-group differences in the number of patients giving the
correct responses to PKQ items or mean PKQ scores at any time
point. Over the follow-up period, the patients in both groups
revealed a trend of increase in their total PKQ scores, but this
was only signiﬁcant in the ENAT group. See table 3.
Educational needs (ENAT scores) of patients in IG
The ﬁrst screening question on ENAT asks patients if they want
any education about their arthritis (yes/no response). At week 0,
33 patients (48%) responded with a ‘yes’ and this dropped to
13 (21%) at week 16 and 9 (16%) by week 32 (x22=18.76,
p<0.001). Table 4 presents ENAT scores over time. There was a
change in the amount of knowledge patients wanted over time
with less people wanting to know everything by week 32, the
change was statistically signiﬁcant, though not at week 16 (week
Table 1 Baseline characteristics of study population by treatment
group
Patient characteristics
and outcomes
Control
group (N=60)
Intervention
group (N=68)
Patient characteristics
Mean age in years (SD) 56 (13.3) 54 (12.3)
Male (%) 22 (37%) 22 (32%)
Disease duration in years (SD) 6.7 (8.9) 5.2 (4.9)
Left school after 16 years of age (%) 20 (32%) 15 (21%)
Studied since leaving school (%) 29 (48%) 25 (37%)
Outcomes Mean (SD) Mean (SD)
ASES (score range)
ASES-Pain (5–50) 25 (11.2) 23 (9.1)
ASES-Other symptoms (6–60) 34 (12.7) 31 (11.5)
AIMS2-SF (score range)
AIMS2-SF: physical (0–10) 3.1 (2.59) 3.1 (2.03)
AIMS2-SF: symptoms (0–10) 5.0 (3.23) 5.4 (2.64)
AIMS2-SF: affect (0–10) 3.7 (2.13) 4.3 (2.19)
AIMS2-SF: social (0–10) 5.5 (1.73) 5.6 (1.75)
AIMS2-SF: work* (0–10) 2.0 (2.69) 2.3 (3.08)
ENAT† (score range)‡
Managing pain (0–18) – 13.3 (3.68)
Movement (0–15) – 11.0 (2.88)
Feelings (0–12) – 7.7 (3.22)
Arthritis process (0–21) – 16.0 (3.90)
Treatments (0–21) – 15.4 (4.43)
Self-help measures (0–18) – 12.6 (4.10)
Support (0–12) – 7.9 (2.65)
*Scores are only available for the 59 (26, 33) patients who were working.
†ENAT was used in the intervention group only.
‡ENAT scores are Rasch-transformed values.
AIMS2-SF, short-form of arthritis impact measurement scale (zero=good health
status); ASES, Arthritis Self Efficacy Scale (higher score=greater self-efficacy); ENAT,
Educational Needs Assessment Tool (zero=no need).
Table 2 Follow-up data for self-efficacy and health status and between-group differences after adjusting for baseline values using analysis of
covariance (results of intention-to-treat analyses)
Control group (N=60) Intervention group (N=68) Mean difference
Domain—time point (range) Mean (95% CI) Mean (95% CI) ENAT-usual care (95% CI) T-statistic (p value)
ASES (score range; higher score=greater self-efficacy)
ASES-Pain—week 16 (5–50) 25.8 (23.8 to 27.8) 27.7 (26.2 to 29.2) 1.86 (−0.63 to 4.35) 1.48 (0.142)*
ASES-Pain —week 32 (5–50) 26.9 (25.2 to 28.5) 31.2 (30.0 to 32.5) 4.36 (1.17 to 7.55) 2.72 (0.008) *
ASES-Other symptoms—week 16 (6–60) 33.5 (31.6 to 35.5) 35.8 (34.2 to 37.3) 2.22 (−1.15 to 5.59) 1.31 (0.194)*
ASES-Other symptoms—week 32 (6–60) 34.0 (32.4 to 35.7) 39.9 (38.6 to 41.1) 5.84 (2.07 to 9.62) 3.07 (0.003)*
AIMS2-SF (score range; zero=good health status)
AIMS2-SF: physical—week 16 (0–10) 3.01 (2.56 to 3.47) 2.81 (2.47 to 3.15) −0.21 (−0.72 to 0.30) −0.83 (0.409)
AIMS2-SF: physical—week 32 (0–10) 3.05 (2.56 to 3.53) 2.84 (2.48 to 3.20) −0.21 (−0.76 to 0.34) −0.77 (0.442)
AIMS2-SF: symptoms—week 16 (0–10) 4.77 (4.16 to 5.38) 4.56 (4.09 to 5.03) −0.21 (−0.93 to 0.52) −0.57 (0.572)
AIMS2-SF: symptoms—week 32 (0–10) 5.25 (4.76 to 5.74) 4.21 (3.79 to 4.63) −1.04 (−1.85 to −0.22) −5.54 (0.013)
AIMS2-SF: affect—week 16 (0–10) 4.00 (3.59 to 4.41) 3.84 (3.44 to 4.24) −0.15 (−0.58 to 0.27) −0.71 (0.479)
AIMS2-SF: affect—week 32 (0–10) 4.29 (3.94 to 4.64) 3.44 (3.10 to 3.78) −0.86 (−1.46 to −0.26) −2.84 (0.006)
AIMS2-SF: social week 16 (0–10) 5.60 (5.22 to 5.98) 5.45 (5.09 to 5.81) −0.15 (−0.51 to 0.21) −0.82 (0.414)
AIMS2-SF: social week 32 (0–10) 5.79 (5.44 to 6.14) 5.67 (5.34 to 6.00) −0.12 (−0.61 to 0.38) −0.47 (0.638)
AIMS2-SF: work†—week 16 (0–10) 3.47 (2.90 to 4.04) 2.70 (2.12 to 3.28) −0.77 (−2.28 to 0.74) −1.02 (0.311)
AIMS2-SF: work†—week 32 (0–10) 2.44 (1.99 to 2.89) 2.71 (2.25 to 3.17) 0.27 (−2.09 to 2.64) 0.24 (0.810)
AIMS2-SF, short form of arthritis impact measurement scale; ASES, Arthritis Self Efficacy Scale; ENAT, Educational Needs Assessment Tool.
*Bonferroni-adjusted p value=0.025 for significance at the α level.
†All missing data imputed except for AIMS2-SF: work where scores are only available for the patients who were working, week 16 and week 32 usual care N=26, intervention N=33.
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0 vs week 16 x23=5.12, p=0.163; week 0 vs week 32x
2
3=8.06,
p=0.045). The ENAT domain scores dropped between week 0
and week 16. Repeated measures analysis revealed signiﬁcant
decrease in all ENAT domain scores (except feelings) and the
total ENAT score.
DISCUSSION
While ENAT has been validated in several countries across
Europe31–33 and it has been used in research as an outcome
measure, this was the ﬁrst RCT to assess its effects on patients’
outcomes. This pragmatic study has demonstrated the effects of
using ENAT as a template from which to give need-based
patient education in normal clinical settings. In this study,
although both groups were provided with patient education by
an experienced CNS and had the same consultation duration,
IG saw signiﬁcant improvements in self-efﬁcacy and some
aspects of health status compared with CG at 32 weeks
follow-up. This suggests that the needs-based education adds
Table 3 Mean score changes (95% CI) in the outcome measures over time*
Week 0 Week 16 Week 32
Control group (N=60) Mean (95% CI) Mean (95% CI) Mean (95% CI) F2,118 (p value)
ASES (score range; higher score=greater self-efficacy)
ASES-Pain (5–50) 25.3 (22.4 to 28.2) 26.5 (23.9 to 29.2) 27.5 (24.6 to 30.3) 2.03 (0.135)†
ASES-Other symptoms (6–60) 34.2 (30.9 to 37.4) 35.0 (31.4 to 38.6) 35.3 (31.5 to 39.0) 0.40 (0.673)†
AIMS2-SF (score range; zero=good health status)
AIMS2: physical (0–10) 3.1 (2.4 to 3.8) 3.0 (2.4 to 3.6) 3.0 (2.4 to 3.7) 0.09 (0.917)
AIMS2: symptoms (0–10) 5.0 (4.2 to 5.8) 4.6 (3.8 to 5.4) 5.1 (4.2 to 6.0) 2.34 (0.101)
AIMS2: affect(0–10) 3.7 (3.2 to 4.3) 3.8 (3.3 to 4.2) 4.1 (3.5 to 4.7) 2.18 (0.117)
AIMS2: social(0–10) 5.5 (5.1 to 6.0) 5.6 (5.1 to 6.0) 5.7 (5.3 to 6.2) 1.86 (0.160)
AIMS2: work‡(0–10) 2.0 (0.9 to 3.1) 3.4 (1.9 to 4.8) 2.4 (−0.01 to 4.8) 3.84 (0.028)
PKQ (score range, higher score=higher level of knowledge)
Total PKQ (0–12) 8.6 (7.9 to 9.2) 8.7 (8.1 to 9.3) 9.1 (8.4 to 9.8) 1.96 (0.146)
Intervention group (N=68) Mean (95% CI) Mean (95% CI) Mean (95% CI) F2,134 (p value)
ASES(score range; higher score=greater self-efficacy)
ASES-Pain (5–50) 23.4 (21.2 to 25.6) 27.0 (24.6 to 29.4) 30.7 (28.2 to 33.2) 37.5 (<0.001)†
ASES-Other symptoms (6–60) 30.6 (27.8 to 33.4) 34.5 (31.4 to 37.5) 38.7 (35.7 to 41.7) 37.2 (<0.001)†
AIMS2-SF (score range; zero=good health status)
AIMS2: physical (0–10) 3.1 (2.6 to 3.6) 2.8 (2.3 to 3.3) 2.8 (2.3 to 3.4) 2.35 (0.099)
AIMS2: symptoms (0–10) 5.4 (4.8 to 6.1) 4.7 (4.0 to 5.4) 4.3 (3.7 to 5.0) 11.8 (<0.001)
AIMS2: affect (0–10) 4.3 (3.8 to 4.8) 4.1 (3.5 to 4.6) 3.6 (3.1 to 4.1) 12.0 (<0.001)
AIMS2: social (0–10) 5.6 (5.2 to 6.0) 5.5 (5.0 to 6.0) 5.7 (5.2 to 6.2) 1.35 (0.263)
AIMS2: work‡(0–10) 2.3 (1.2 to 3.4) 2.8 (1.6 to 3.9) 2.8 (1.5 to 5.0) 0.60 (0.552)
PKQ (score range, higher score=higher level of knowledge)
Total PKQ (0–12) 8.6 (8.0 to 9.1) 9.0 (8.5 to 9.5) 9.2 (8.7 to 9.8) 5.22 (0.007)
*Analysis not adjusted for baseline values as examining changes over time including values at baseline.
†Bonferroni-adjusted p value=0.025 for significance at the α level.
‡All missing data imputed except for AIMS2-SF: Work where scores are only available for the patients who were working, week 16 and week 32 control group N=26 and intervention
group N=33.
ASES, Arthritis Self Efficacy Scale; PKQ, patient knowledge questionnaire.
Table 4 Change in educational needs assessment tool (ENAT) scores* over time
Week 0 (N=68) Week 16 (N=68) Week 32 (N=68)
Initial question of need N (%) N (%) N (%)
Do not want to know anything 2 (3) 3 (4) 5 (7)
Want to know some things 15 (22) 24 (35) 25 (37)
Want to know lots of things 10 (15) 13 (19) 13 (19)
Want to know everything 41 (60) 28 (41) 25 (37)
ENAT domains (score range)* Mean*(95% CI) Mean* (95% CI) Mean* (95% CI) F2,107 (p value)
Managing pain (0–18) 13.3 (12.4 to 14.2) 12.2 (11.1 to 13.3) 11.5 (10.5 to 12.5) 8.07 (0.001)
Movement (0–15) 11.0 (10.3 to 11.7) 10.0 (9.1 to 10.9) 9.9 (9.1 to 10.7) 3.16 (0.046)
Feelings (0–12) 7.7 (6.9 to 8.5) 6.9 (6.0 to 7.9) 6.9 (6.1 to 7.7) 2.09 (0.129)
Arthritis process (0–21) 16.0 (15.1 to 17.0) 14.2 (13.0 to 15.3) 14.2 (13.0 to 15.4) 6.23 (0.003)
Treatments (0–21) 15.4 (14.3 to 16.5) 14.5 (13.4 to 15.5) 13.7 (12.6 to 14.8) 3.46 (0.035)
Self-help measures (0–18) 12.6 (11.6 to 13.6) 11.3 (10.2 to 12.4) 10.7 (9.6 to 11.9) 8.02 (0.001)
Support (0–12) 7.9 (7.3 to 8.5) 7.3 (6.5 to 8.1) 6.5 (5.8 to 7.3) 5.93 (0.004)
Total ENAT score (0–117) 83.9 (79.2 to 88.6) 76.3 (70.4 to 82.3) 73.8 (67.8 to 79.7) 7.53 (0.001)
*The ENAT domain scores are Rasch-transformed values, see scoring guide in the online supplementary material.
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value to this provision by improving self-efﬁcacy and by ensur-
ing that patients’ priority educational needs are being met.
Self-efﬁcacy is important for people with arthritis who are
expected to undertake self-management activities and adhere to
different therapeutic interventions in addition to their family
roles and work. In chronic disease, self-efﬁcacy has been shown
to mediate the effects of education onto other outcomes such as
pain, physical health status and mental health status and
health-related quality of life.9 11 12 This is likely to explain the
improvement in the AIMS2-SF symptoms and AIMS2-SF affect
that was seen in IG. In a 5-year observational study, Brekke
et al9 found signiﬁcant correlations between changes in self-
efﬁcacy and changes in AIMS2-Symptoms and AIMS2-Affect
but not the AIMS2-Physical or AIMS2-Social subscales. It is
perhaps not surprising that our 6-month study did not show
improvements in these subscales.
The results on overall patient knowledge were interesting as
there were no signiﬁcant between-group differences in the mean
PKQ scores at any time point. However, the PKQ scores within
IG increased signiﬁcantly, coupled with a decrease in their
ENAT scores, which suggests that patients’ speciﬁc educational
needs were being met. It is worth pointing out here that ENAT
is meant to assess patients’ educational needs, not knowledge,
therefore the use of ENAT may not result in an increase in the
overall knowledge about RA. It is hoped that the clinician will
use their own assessment skills in addition to ENAT as a simple
tool to objectively address areas that are of greatest need from
the patients’ point of view. Once the clinician has addressed
patient’s priority educational needs, other important aspects of
patient education can be introduced such as need for switching
drugs or cardiovascular risks.
Qualitative study of patients’ views and clinical usability of
ENAT has demonstrated patients’ and nurses’ acceptability of
the tool.45 Patients’ completion of ENAT enables them to think
of questions which they would not have otherwise considered,
this helps them to objectively and effectively identify their own
educational needs and helps the clinicians to target areas that
are often overlooked but important to patients such as sexual
activity and support groups. This needs-based approach is likely
to ensure that patients’ educational needs are being met effect-
ively and that they are enabled to self-manage their disease and
maximise their coping strategies.
This study had four main strengths. First, being a pragmatic
RCT implies that the effects of ENAT demonstrated in this
study have taken into account everyday clinical practice,
meaning that it is feasible to use ENAT in normal clinical set-
tings and expect similar results. Second, being a multicentre
study, the results are applicable to more than just one centre.
Third, being a single-blind (participants) RCT helped reduce
biased responses. Lastly, undertaking an intention-to-treat ana-
lysis with multiple imputations for the missing values, helped to
reduce bias in the assessment of treatment effects. The excep-
tion to this approach was the AIMS2-SF work data which was
not imputed.
This study had four main limitations. First, the follow-up
period was only 6 months and since RA is a variable disease a
longer follow-up period would have been desirable in order to
reﬂect the long-term effects of needs-based education. However,
it is expected that changes in self-efﬁcacy especially early in the
disease may contribute towards long-term effects in health out-
comes.9 Second, although the between-group differences in
both ASES subscales were highly signiﬁcant at week 32, the pre-
hypothesised difference36 of 5.5 was not reached in the
ASES-Pain subscale and we do not know if the associated
changes in the AIMS2-SF subscales are large enough to be clin-
ically signiﬁcant. Third, the effectiveness of individual patient
education may be inﬂuenced by how CNS relate to their
patients. Since we did not measure this factor, and given that
both interventions were provided by the same CNS, there may
be a potential risk of performance bias by the intervention pro-
viders. Lastly, since the practitioners participating in this study
were all CNS running nurse-led clinics, we do not know if
ENAT would have had the same effects in rheumatologist-led
clinics. Since rheumatologists’ clinics are characterised by
problem-based interaction style and provision of factual biomed-
ical information,46 47 it is plausible to expect at least the same
results from the use of ENAT in their consultations.
In conclusion, since targeted education is recommended as an
integral part of management of RA,6 8 ENAT is a worthy tool
which should be given serious consideration as a template upon
which to guide individualised patient education. The results of
this RCT suggest that need-based education helps improve
patients’ self-efﬁcacy and some aspects of health status. Further
research is required to determine the time in the RA trajectory
where focused, patient-centred education has its maximum
effects. Future developments of ENATwill ensure that the tool
remains current and useful in connecting patients to available
resources and services.
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